- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06101095
Um estudo que avalia a função e remodelação esofágica com dupilumabe em comparação com placebo por 24 semanas seguidas de 104 semanas de rótulo aberto em participantes adultos com EEo (REMOdeling With Dupilumab in Eosinophilic Esofagite Long-term Trial)
Um estudo de fase 4, randomizado, multicêntrico, duplo-cego, grupo paralelo, 24 semanas, controlado por placebo, seguido de 104 semanas aberto para avaliar a eficácia do dupilumabe na função e remodelação esofágica em participantes adultos com esofagite eosinofílica (EoE)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
- Screening period: Up to 12 weeks before Week 0
- Randomized double-blind period: 24 weeks
- Open label period: 104 weeks
- Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.
There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The duration per participant will be up to 152 weeks.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
São Paulo, Brasil, 01323-020
- Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41825-010
- Itaigara Memorial - Hospital Dia- Site Number : 0760005
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
-
-
São Paulo
-
Campinas, São Paulo, Brasil, 13010-001
- Clínica Loema - Unidade I- Site Number : 0760007
-
Sorocaba, São Paulo, Brasil, 18040-425
- Clinica de Alergia Martti Antila- Site Number : 0760001
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Investigational Site Number : 1240006
-
Vancouver, British Columbia, Canadá, V6Z 2K5
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Canadá, H4A 3T2
- Investigational Site Number : 1240002
-
-
-
-
California
-
Murrieta, California, Estados Unidos, 92563
- United Gastroenterologists - Murrieta- Site Number : 8400001
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco - Parnassus Heights- Site Number : 8400020
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32256
- Borland Groover Clinic- Site Number : 8400016
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Treasure Valley Medical Research- Site Number : 8400018
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University- Site Number : 8400003
-
Glenview, Illinois, Estados Unidos, 60026
- GI Alliance - Glenview- Site Number : 8400012
-
Gurnee, Illinois, Estados Unidos, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa- Site Number : 8400006
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01655
- University of Massachusetts Chan Medical School- Site Number : 8400019
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic Hospital Rochester- Site Number : 8400008
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- University of North Carolina at Chapel Hill- Site Number : 8400007
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400009
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
-
-
Texas
-
Houston, Texas, Estados Unidos, 77087
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015
-
Mansfield, Texas, Estados Unidos, 76063
- GI Alliance - Mansfield- Site Number : 8400017
-
-
-
-
-
Haifa, Israel, 3104802
- Investigational Site Number : 3760006
-
Haifa, Israel, 3109601
- Investigational Site Number : 3760002
-
Jerusalem, Israel, 9103102
- Investigational Site Number : 3760005
-
Jerusalem, Israel, 9112001
- Investigational Site Number : 3760004
-
Tel Aviv, Israel, 6423906
- Investigational Site Number : 3760003
-
-
-
-
-
Wetzikon, Suíça, 8620
- Investigational Site Number : 7560001
-
Zurich, Suíça, 8091
- Investigational Site Number : 7560002
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A documented diagnosis of EoE by endoscopic biopsy.
- Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
- History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
- Body weight ≥40 kg.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
- Active Helicobacter pylori infection.
- History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
- Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
- History of bleeding disorders or esophageal varices.
- Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.
- Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
- Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
SC injection as per protocol |
SC injection as per protocol |
|
Experimental: Dupilumab
Subcutaneous injection (SC) as per protocol |
Subcutaneous injection (SC) as per protocol |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Prazo: From baseline to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline to Week 24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidência de eventos adversos emergentes do tratamento (TEAEs) e eventos adversos graves (SAEs)
Prazo: Desde a primeira administração do ME até o final do período de acompanhamento pós-tratamento (semana 139)
|
Desde a primeira administração do ME até o final do período de acompanhamento pós-tratamento (semana 139)
|
|
|
Incidência de eventos adversos de interesse especial (EAIE)
Prazo: Desde a primeira administração do ME até o final do período de acompanhamento pós-tratamento (semana 139)
|
Desde a primeira administração do ME até o final do período de acompanhamento pós-tratamento (semana 139)
|
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Prazo: From baseline up to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week 24
|
|
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Prazo: From baseline up to Week128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week128
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Prazo: From Baseline up to Week 128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From Baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)
Prazo: From baseline up to Week 128
|
EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease. |
From baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
Prazo: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Change from baseline in EoE-HSS Stage
Prazo: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)
Prazo: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF
Prazo: At Week 24
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Week 24
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF
Prazo: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature
Prazo: From baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From baseline up to Week 128 (EOT)
|
|
Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature
Prazo: From Baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From Baseline up to Week 128 (EOT)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Clinical Sciences & Operations, Sanofi
Publicações e links úteis
Publicações Gerais
- Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simoes Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.
- Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025.
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LPS17558
- U1111-1280-5266 (Identificador de registro: ICTRP)
- 2022-502491-23 (Identificador de registro: CTIS)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .